Abstract：
OBJECTIVE: There is limited data on the incidence, prevalence, and treatments for myelofibrosis (MF) in Germany. This retrospective study examined claims data from 3.3 million insured individuals, spanning from 2010 to 2021.
METHODS: Four sensitivity scenarios were explored to identify cases of MF. Point prevalence and cumulative incidence of MF were determined as of December 31, 2021, and within 2021, respectively. A cross-sectional analysis used the main scenario definition of MF to identify cases and evaluate the period prevalence of patients receiving treatment for symptoms and/or splenomegaly, including first-line (1L) Janus kinase inhibitor (JAKi), second-line, or further (2L+) MF-related treatment therapies during 2021. The prevalence of anemia treatment was also reported.
RESULTS: The estimated standardized point prevalence of MF on December 31, 2021, was 9.9-12.4 cases per 100 000 persons, and cumulative incidence in 2021 was 1.2-1.8 cases per 100 000 persons. Standardized period prevalence in 2021 for MF patients receiving 1L JAKi and/or 2L+ MF-related treatment was 4.0 cases per 100 000. Among these patients, 47.1%-53.7% required treatment for anemia, resulting in a period prevalence of 1.9-2.2 cases per 100 000 individuals.
CONCLUSIONS: The data reveal gaps in MF treatments and the need to improve patient quality of life.
METHODS: Four sensitivity scenarios were explored to identify cases of MF. Point prevalence and cumulative incidence of MF were determined as of December 31, 2021, and within 2021, respectively. A cross-sectional analysis used the main scenario definition of MF to identify cases and evaluate the period prevalence of patients receiving treatment for symptoms and/or splenomegaly, including first-line (1L) Janus kinase inhibitor (JAKi), second-line, or further (2L+) MF-related treatment therapies during 2021. The prevalence of anemia treatment was also reported.
RESULTS: The estimated standardized point prevalence of MF on December 31, 2021, was 9.9-12.4 cases per 100 000 persons, and cumulative incidence in 2021 was 1.2-1.8 cases per 100 000 persons. Standardized period prevalence in 2021 for MF patients receiving 1L JAKi and/or 2L+ MF-related treatment was 4.0 cases per 100 000. Among these patients, 47.1%-53.7% required treatment for anemia, resulting in a period prevalence of 1.9-2.2 cases per 100 000 individuals.
CONCLUSIONS: The data reveal gaps in MF treatments and the need to improve patient quality of life.
摘要：
目的：关于发病率的数据有限，患病率,和治疗骨髓纤维化（MF）在德国。这项回顾性研究检查了330万被保险人的索赔数据，从2010年到2021年。
方法：探索了四种敏感性情景来识别MF病例。MF的点患病率和累积发病率分别于2021年12月31日和2021年内确定。横断面分析使用MF的主要情景定义来识别病例并评估接受症状和/或脾肿大治疗的患者的时期患病率。包括一线（1L）Janus激酶抑制剂（JAKI），第二行,或2021年进一步的（2L+）MF相关治疗疗法。还报道了贫血治疗的患病率。
结果：2021年12月31日估计的MF标准化点患病率为每10万人9.9-12.4例，2021年的累计发病率为每10万人1.2-1.8例。2021年接受1LJAKI和/或2L+MF相关治疗的MF患者的标准化期患病率为4.0例/10万。在这些患者中,47.1％-53.7％的贫血需要治疗，导致每10万人中1.9-2.2例。
结论：数据揭示了MF治疗的差距和改善患者生活质量的需要。
方法：探索了四种敏感性情景来识别MF病例。MF的点患病率和累积发病率分别于2021年12月31日和2021年内确定。横断面分析使用MF的主要情景定义来识别病例并评估接受症状和/或脾肿大治疗的患者的时期患病率。包括一线（1L）Janus激酶抑制剂（JAKI），第二行,或2021年进一步的（2L+）MF相关治疗疗法。还报道了贫血治疗的患病率。
结果：2021年12月31日估计的MF标准化点患病率为每10万人9.9-12.4例，2021年的累计发病率为每10万人1.2-1.8例。2021年接受1LJAKI和/或2L+MF相关治疗的MF患者的标准化期患病率为4.0例/10万。在这些患者中,47.1％-53.7％的贫血需要治疗，导致每10万人中1.9-2.2例。
结论：数据揭示了MF治疗的差距和改善患者生活质量的需要。
